|
|
Interferon-α salvage treatment is effective for patients with acute leukemia/myelodysplastic syndrome with unsatisfactory response to minimal residual disease-directed donor lymphocyte infusion after allogeneic hematopoietic stem cell transplantation |
Xiaodong Mo1, Xiaohui Zhang1, Lanping Xu1, Yu Wang1, Chenhua Yan1, Huan Chen1, Yuhong Chen1, Wei Han1, Fengrong Wang1, Jingzhi Wang1, Kaiyan Liu1, Xiaojun Huang1,2() |
1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China 2. Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing 100044, China |
|
|
Abstract The efficacy of salvage interferon-α (IFN-α) treatment was investigated in patients with unsatisfactory response to minimal residual disease (MRD)-directed donor lymphocyte infusion (DLI) (n=24). Patients who did not become MRD-negative at 1 month after DLI were those with unsatisfactory response and were eligible to receive salvage IFN-α treatment within 3 months of DLI. Recombinant human IFN-α-2b injections were subcutaneously administered 2–3 times a week for 6 months. Nine (37.5%), 6 (25.0%), and 3 (12.5%) patients became MRD-negative at 1, 2, and>2 months after the salvage IFN-α treatment, respectively. Two-year cumulative incidences of relapse and non-relapse mortality were 35.9% and 8.3%, respectively. Two-year probabilities of event-free survival, disease-free survival, and overall survival were 51.6%, 54.3%, and 68.0%, respectively. Outcomes of patients subjected to salvage IFN-α treatment after DLI were significantly better than those with persistent MRD without IFN-α treatment. Moreover, clinical outcomes were comparable between the salvage DLI and IFN-α treatment groups. Thus, salvage IFN-α treatment may help improve the outcome of patients with unsatisfactory responses to MRD-directed DLI and could be a potential salvage treatment for these patients after allogeneic hematopoietic stem cell transplantation.
|
Keywords
interferon-α
hematopoietic stem cell transplantation
minimal residual disease
donor lymphocyte infusion
|
Corresponding Author(s):
Xiaojun Huang
|
Just Accepted Date: 12 February 2018
Online First Date: 16 April 2018
Issue Date: 28 March 2019
|
|
1 |
PTsirigotis, M Byrne, CSchmid, FBaron, FCiceri, JEsteve, NCGorin, SGiebel, MMohty, BNSavani, ANagler. Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT. Bone Marrow Transplant 2016; 51(11): 1431–1438
https://doi.org/10.1038/bmt.2016.167
pmid: 27295272
|
2 |
PTsirigotis, M Liga, KGkirkas, MStamouli, ETriantafyllou, MMarangos, IPessach, ASarantopoulos, NSpyridis, ASpyridonidis. Low-dose alemtuzumab for GvHD prevention followed by prophylactic donor lymphocyte infusions in high-risk leukemia. Bone Marrow Transplant 2017; 52(3): 445–451
https://doi.org/10.1038/bmt.2016.272
pmid: 27941776
|
3 |
ADominietto, S Pozzi, MMiglino, FAlbarracin, GPiaggio, FBertolotti, RGrasso, SZupo, AM Raiola, MGobbi, FFrassoni, ABacigalupo. Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia. Blood 2007; 109(11): 5063–5064
https://doi.org/10.1182/blood-2007-02-072470
pmid: 17522340
|
4 |
CHYan, DH Liu, KYLiu, LPXu, YR Liu, HChen, WHan, Y Wang, YZQin, XJHuang. Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood 2012; 119(14): 3256–3262
https://doi.org/10.1182/blood-2011-09-380386
pmid: 22337715
|
5 |
XDMo, XH Zhang, LPXu, YWang, CH Yan, HChen, YHChen, WHan, FR Wang, JZWang, KYLiu, XJ Huang. Salvage chemotherapy followed by granulocyte colony-stimulating factor-primed donor leukocyte infusion with graft-vs.-host disease control for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: prognostic factors and clinical outcomes. Eur J Haematol 2016; 96(3): 297–308
https://doi.org/10.1111/ejh.12591
pmid: 26010204
|
6 |
ENMcSweeney, CP Worman, CPTsakona, APJewel, AVHoffbrand, DWMilligan, AKBurnett, MLLewis, AHGoldstone. Low-dose recombinant alfa-2a-interferon: a feasible maintenance therapy in acute myeloid leukaemia in the older patient. Acta Haematol 1993; 89(1): 1–5
pmid: 8480480
|
7 |
ELSmits, S Anguille, ZNBerneman. Interferon α may be back on track to treat acute myeloid leukemia. OncoImmunology 2013; 2(4): e23619
https://doi.org/10.4161/onci.23619
pmid: 23734314
|
8 |
SAnguille, E Lion, YWillemen, VFVan Tendeloo, ZNBerneman, ELSmits. Interferon-α in acute myeloid leukemia: an old drug revisited. Leukemia 2011; 25(5): 739–748
https://doi.org/10.1038/leu.2010.324
pmid: 21274002
|
9 |
SSinghal, R Powles, JTreleaven, JMehta. Sensitivity of secondary acute myeloid leukemia relapsing after allogeneic bone marrow transplantation to immunotherapy with interferon-α2b. Bone Marrow Transplant 1997; 19(11): 1151–1153
https://doi.org/10.1038/sj.bmt.1700793
pmid: 9193760
|
10 |
BGesundheit, MY Shapira, IBResnick, AAmar, D Kristt, LDray, EBudowski, ROr. Successful cell-mediated cytokine-activated immunotherapy for relapsed acute myeloid leukemia after hematopoietic stem cell transplantation. Am J Hematol 2009; 84(3): 188–190
https://doi.org/10.1002/ajh.21346
pmid: 19105234
|
11 |
XTang, YH Song, ASun, XZhu, C Ruan, DWu. Successful treatment of relapsed acute myeloid leukemia without chemotherapy. J Clin Oncol 2016; 34(13): e117–e119
https://doi.org/10.1200/JCO.2012.48.0442
pmid: 24711555
|
12 |
XDMo, XH Zhang, LPXu, YWang, CH Yan, HChen, YHChen, WHan, FR Wang, JZWang, KYLiu, XJ Huang. Interferon-α: a potentially effective treatment for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2015; 21(11): 1939–1947
https://doi.org/10.1016/j.bbmt.2015.06.014
pmid: 26116088
|
13 |
XMo, X Zhao, LXu, DLiu, X Zhang, HChen, YWang, X Huang. Interferon α: the salvage therapy for patients with unsatisfactory response to minimal residual disease-directed modified donor lymphocyte infusion. Chin Med J (Engl) 2014; 127(14): 2583–2587
pmid: 25043071
|
14 |
XJHuang, LP Xu , KYLiu , DHLiu , Y Wang , HChen , YHChen , WHan , JZ Wang , YChen , XHZhang , HXShi , FR Wang , FFTang . Partially matched related donor transplantation can achieve outcomes comparable with unrelated donor transplantation for patients with hematologic malignancies. Clin Cancer Res 2009; 15(14): 4777–4783
https://doi.org/10.1158/1078-0432.CCR-09-0691
pmid: 19584148
|
15 |
YWang, QF Liu, LPXu, KYLiu, XH Zhang, XMa, ZPFan, DP Wu, XJHuang. Haploidentical vs. identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood 2015; 125(25): 3956–3962
https://doi.org/10.1182/blood-2015-02-627786
pmid: 25940714
|
16 |
XJHuang, DH Liu, KYLiu, LPXu, H Chen, WHan, YHChen, JZWang, ZYGao, YC Zhang, QJiang, HXShi, DP Lu. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2006; 38(4): 291–297
https://doi.org/10.1038/sj.bmt.1705445
pmid: 16883312
|
17 |
XJHuang, DH Liu, KYLiu, LPXu, H Chen, WHan, YHChen, XHZhang, DPLu. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant 2009; 15(2): 257–265
https://doi.org/10.1016/j.bbmt.2008.11.025
pmid: 19167686
|
18 |
XSZhao, YR Liu, HHZhu, LPXu, DH Liu, KYLiu, XJHuang. Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation. Ann Hematol 2012; 91(2): 183–192
https://doi.org/10.1007/s00277-011-1285-1
pmid: 21710165
|
19 |
HHZhu, XH Zhang, YZQin, DHLiu, H Jiang, HChen, QJiang, LPXu, J Lu, WHan, LBao, Y Wang, YHChen, JZWang, FRWang, YYLai, JY Chai, LRWang, YRLiu, KY Liu, BJiang, XJHuang. MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood 2013; 121(20): 4056–4062
https://doi.org/10.1182/blood-2012-11-468348
pmid: 23535063
|
20 |
YWang, DP Wu, QFLiu, YZQin, JB Wang, LPXu, YRLiu, HH Zhu, JChen, MDai, XJ Huang. In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification. Blood 2014; 124(12): 1880–1886
https://doi.org/10.1182/blood-2014-03-563403
pmid: 25082877
|
21 |
XSZhao, S Jin, HHZhu, LPXu, DH Liu, HChen, KYLiu, XJ Huang. Wilms’ tumor gene 1 expression: an independent acute leukemia prognostic indicator following allogeneic hematopoietic SCT. Bone Marrow Transplant 2012; 47(4): 499–507
https://doi.org/10.1038/bmt.2011.121
pmid: 21643023
|
22 |
XSZhao, CH Yan, DHLiu, LPXu, YR Liu, KYLiu, YZQin, Y Wang, XJHuang. Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity. Ann Hematol 2013; 92(8): 1111–1119
https://doi.org/10.1007/s00277-013-1733-1
pmid: 23680867
|
23 |
XDMo, XH Zhang, LPXu, YWang, CH Yan, HChen, YHChen, WHan, FR Wang, JZWang, KYLiu, XJ Huang. Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. Ann Hematol 2017; 96(5): 829–838
https://doi.org/10.1007/s00277-017-2960-7
pmid: 28285386
|
24 |
FLDignan, A Clark, PAmrolia, JCornish, GJackson, PMahendra, JJScarisbrick, PCTaylor, NHadzic, BEShaw, MNPotter; Haemato-oncology Task Force of British Committee for Standards in Haematology; British Society for Blood and Marrow Transplantation. Diagnosis and management of acute graft-versus-host disease. Br J Haematol 2012; 158(1): 30–45
https://doi.org/10.1111/j.1365-2141.2012.09129.x
pmid: 22533831
|
25 |
FLDignan, P Amrolia, AClark, JCornish, GJackson, PMahendra, JJScarisbrick, PCTaylor, BEShaw, MNPotter; Haemato-oncology Task Force of British Committee for Standards in Haematology; British Society for Blood and Marrow Transplantation. Diagnosis and management of chronic graft-versus-host disease. Br J Haematol 2012; 158(1): 46–61
https://doi.org/10.1111/j.1365-2141.2012.09128.x
pmid: 22533811
|
26 |
PArmand, CJ Gibson, CCutler, VTHo, J Koreth, EPAlyea, JRitz, ML Sorror, SJLee, HJDeeg, BEStorer, FRAppelbaum, JHAntin, RJSoiffer, HTKim. A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood 2012; 120(4): 905–913
https://doi.org/10.1182/blood-2012-03-418202
pmid: 22709687
|
27 |
DPrzepiorka, D Weisdorf, PMartin, HGKlingemann, PBeatty, JHows, ED Thomas. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15(6): 825–828
pmid: 7581076
|
28 |
AHFilipovich, D Weisdorf, SPavletic, GSocie, JRWingard, SJLee, P Martin, JChien, DPrzepiorka, DCouriel, EWCowen, PDinndorf, AFarrell, RHartzman, JHenslee-Downey, DJacobsohn, GMcDonald, BMittleman, JDRizzo, MRobinson, MSchubert, KSchultz, HShulman, MTurner, GVogelsang, MEFlowers. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11(12): 945–956
https://doi.org/10.1016/j.bbmt.2005.09.004
pmid: 16338616
|
29 |
TAGooley, W Leisenring, JCrowley, BEStorer. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18(6): 695–706
https://doi.org/10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O
pmid: 10204198
|
30 |
AZRohatiner. Growth inhibitory effects of interferon on blast cells from patients with acute myelogenous leukaemia. Br J Cancer 1984; 49(6): 805–807
https://doi.org/10.1038/bjc.1984.125
pmid: 6587902
|
31 |
SMorecki, S Revel-Vilk, CNabet, MPick, A Ackerstein, ANagler, ENaparstek, MBen Shahar, SSlavin. Immunological evaluation of patients with hematological malignancies receiving ambulatory cytokine-mediated immunotherapy with recombinant human interferon-alpha 2a and interleukin-2. Cancer Immunol Immunother 1992; 35(6): 401–411
https://doi.org/10.1007/BF01789019
pmid: 1394343
|
32 |
XDMo, XH Zhang, LPXu, YWang, CH Yan, HChen, YHChen, WHan, FR Wang, JZWang, KYLiu, XJ Huang. IFN-α is effective for treatment of minimal residual disease in patients with acute leukemia after allogeneic hematopoietic stem cell transplantation: results of a registry study. Biol Blood Marrow Transplant 2017; 23(8): 1303–1310
https://doi.org/10.1016/j.bbmt.2017.04.023
pmid: 28457953
|
33 |
HJKolb, J Mittermüller, CClemm, EHoller, GLedderose, GBrehm, MHeim, W Wilmanns. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76(12): 2462–2465
pmid: 2265242
|
34 |
AGrigg, K Kannan, APSchwarer, ASpencer, JSzer. Chemotherapy and granulocyte colony stimulating factor-mobilized blood cell infusion followed by interferon-α for relapsed malignancy after allogeneic bone marrow transplantation. Intern Med J 2001; 31(1): 15–22
https://doi.org/10.1046/j.1445-5994.2001.00013.x
pmid: 11478351
|
35 |
FBaron, M Labopin, DNiederwieser, SVigouroux, JJCornelissen, CMalm, LL Vindelov, DBlaise, JJJanssen, EPetersen, GSocié, ANagler, VRocha, MMohty. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. Leukemia 2012; 26(12): 2462–2468
https://doi.org/10.1038/leu.2012.135
pmid: 22699419
|
36 |
XDMo, LP Xu, XHZhang, DHLiu, Y Wang, HChen, CHYan, YH Chen, WHan, FRWang, JZWang, KYLiu, XJ Huang. Chronic GVHD induced GVL effect after unmanipulated haploidentical hematopoietic SCT for AML and myelodysplastic syndrome. Bone Marrow Transplant 2015; 50(1): 127–133
https://doi.org/10.1038/bmt.2014.223
pmid: 25387095
|
37 |
TSchroeder, A Czibere, UPlatzbecker, GBug, L Uharek, TLuft, AGiagounidis, FZohren, IBruns, CWolschke, KRieger, RFenk, U Germing, RHaas, NKröger, GKobbe. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia 2013; 27(6): 1229–1235
https://doi.org/10.1038/leu.2013.7
pmid: 23314834
|
38 |
UPlatzbecker, M Wermke, JRadke, UOelschlaegel, FSeltmann, AKiani, IMKlut, HKnoth, CRöllig, JSchetelig, BMohr, X Graehlert, GEhninger, MBornhäuser, CThiede. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia 2012; 26(3): 381–389
https://doi.org/10.1038/leu.2011.234
pmid: 21886171
|
39 |
IChoi, SR Yoon, SYPark, HKim, SJ Jung, YJJang, MKang, YI Yeom, JLLee, DYKim, YS Lee, YAKang, MJeon, M Seol, JHLee, JHLee, HJ Kim, SCYun, KHLee. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study. Biol Blood Marrow Transplant 2014; 20(5): 696–704
https://doi.org/10.1016/j.bbmt.2014.01.031
pmid: 24525278
|
40 |
CRCruz, KP Micklethwaite, BSavoldo, CARamos, SLam, S Ku, ODiouf, ELiu, AJ Barrett, SIto, EJShpall, RAKrance, RTKamble, GCarrum, CMHosing, APGee, Z Mei, BJGrilley, HEHeslop, CMRooney, MKBrenner, CMBollard, GDotti. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 2013; 122(17): 2965–2973
https://doi.org/10.1182/blood-2013-06-506741
pmid: 24030379
|
41 |
YBChen, S Li, AALane, CConnolly, CDel Rio, BValles, MCurtis, KBallen, CCutler, BRDey, A El-Jawahri, ATFathi, VTHo, A Joyce, SMcAfee, MRudek, TRajkhowa, SVerselis, JHAntin, TRSpitzer, MLevis, RSoiffer. Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. Biol Blood Marrow Transplant 2014; 20(12): 2042–2048
https://doi.org/10.1016/j.bbmt.2014.09.007
pmid: 25239228
|
42 |
HGKlingemann, AP Grigg, KWilkie-Boyd, MJBarnett, ACEaves, DEReece, JDShepherd, GLPhillips. Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse [corrected]. Blood 1991; 78(12): 3306–3311 (corrected)
pmid: 1742491
|
43 |
CYan, L Xu, DLiu, HChen, Y Wang, KLiu, XHuang. Immunosuppression for 6-8 weeks after modified donor lymphocyte infusion reduced acute graft-versus-host disease without influencing graft-versus-leukemia effect in haploidentical transplant. Chin Med J (Engl) 2014; 127(20): 3602–3609
pmid: 25316237
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|